Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

The intra-meatal application of alprostadil cream (Vitaros®) improves drug efficacy and patient’s satisfaction: results from a randomized, two-administration route, cross-over clinical trial


To investigate the efficacy, tolerability, and patient’s preference of alprostadil cream for topical use administered within the urethral meatus versus the standard administration route, in erectile dysfunction (ED) treatment. Seventy-one patients (mean age 59.7 ± 9.0 years) affected by ED were analyzed in this multicenter, randomized, two-administration routes, cross-over trial. All patients received a single dose of alprostadil cream applying the dispenser to the tip of the penis (without contacting the urethral meatus) (Standard administration route or ST.AR) alternating with a single dose of alprostadil cream applying the dispenser within the urethral meatus (New administration route or NEW.AR) separated by a one-week washout period, according to randomization. The primary objective of the study was to evaluate the change in International Index of Erectile Function (IIEF-5) total score from baseline to the control visit by comparing the ST.AR and NEW.AR. Secondary objectives of the study were to compare the different methods of administration by evaluating the change in the Sexual Encounter Profile (SEP-2 and SEP-3) questionnaire score and the Patient Reported Outcomes (PROs) by scoring the Patient Self-Assessment of Erection (PSAE) questionnaire. The treatment safety profile was assessed by analysis of adverse events (AEs). Based on the study findings it is evident that the NEW.AR is more efficacious than the ST.AR in improving IIEF-5 and SEP scores from baseline to control visit (IIEF-5: +3.8 vs +6.3; p < 0.001; positive response to SEP-2: 10 vs 27; p = 0.002) and in terms of PSAE (a significant improvement from the baseline in 31% of patients; p < 0.001). As regards the safety profile, no difference in terms of local and systemic side effects was found.

This is a preview of subscription content

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1
Fig. 2


  1. 1.

    Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U. Epidemiology of erectile dysfunction: results of the Cologne Male Survey. Int J Impot Res. 2000;12:305–11.

    CAS  Article  Google Scholar 

  2. 2.

    Liu LH, Zhang T, Zhang YR, Liu TS, Zhang HB, Chen FZ, et al. Metabolic syndrome and risk for ED: a meta-analysis. Int J Impot Res. 2014;26:196–200.

    CAS  Article  Google Scholar 

  3. 3.

    NIH Consensus Development Panel on Impotence. JAMA.1993;270:83–90.

  4. 4.

    Latini DM, Penson DF, Lubeck DP, Wallace KL, Henning JM, Lue TF. Longitudinal differences in disease specific quality of life in men with erectile dysfunction: results from the exploratory comprehensive evaluation of erectile dysfunction study. J Urol. 2003;169:1437–42.

    Article  Google Scholar 

  5. 5.

    Hatzimouratidis K (Chair), Giuliano F, Moncada I, Muneer A, Salonia A (Vice-chair), Verze P. EAU Guidelines on Erectile Dysfunction, Premature Ejaculation, Penile Curvature and Priapism UPDATE MARCH 2018

  6. 6.

    Carvalheira AA, Pereira NM, Maroco J, Forjaz V. Dropout in the treatment of erectile dysfunction with PDE5: a study on predictors and a qualitative analysis of reasons for discontinuation. J Sex Med. 2012;9:2361–9.

    Article  Google Scholar 

  7. 7.

    El-Sakka AI. Intracavernosal prostaglandin E1 self vs office injection therapy in patients with erectile dysfunction. Int J Impot Res. 2006;18:180–5.

    CAS  Article  Google Scholar 

  8. 8.

    Jannini EA, Sternbach N, Limoncin E, Ciocca G, Gravina GL, Tripodi F, et al. Health-related characteristics and unmet needs of men with erectile dysfunction: a survey in five European countries. J Sex Med. 2014;11:40–50.

    Article  Google Scholar 

  9. 9.

    Rooney M, Pfister W, Mahoney M, Nelson M, Yeager J, Steidle C. Long-term, Multicenter Study of the Safety and Efficacy of Topical Alprostadil Cream in Male Patients with Erectile Dysfunction. J Sex Med. 2009;6:520–34.

    CAS  Article  Google Scholar 

  10. 10.

    Padma-Nathan H, Steidle C, Salem S, Tayse N, Yeager J, Harning R. The efficacy and safety of a topical alprostadil cream, Alprox-TD, for the treatment of erectile dysfunction: two phase 2 studies in mild-to-moderate and severe ED. Int J Impot Res. 2003;15:10–17.

    CAS  Article  Google Scholar 

  11. 11.

    Steidle C, Padma-Nathan H, Salem S, Tayse N, Thwing D, Fendl J, et al. Topical alprostadil cream for the treatment of erectile dysfunction: a combined analysis of the phase II program. Urology. 2002;60:1077–82.

    Article  Google Scholar 

  12. 12.

    Padma-Nathan H, Yeager JL. An integrated analysis of alprostadil topical cream for the treatment of erectile dysfunction in 1732 patients. Urology. 2006;68:386–91.

    Article  Google Scholar 

  13. 13.

    Moncada I, Cuzin B. Clinical efficacy and safety of Vitaros©/Virirec© (Alprostadil cream) for the treatment of erectile dysfunction. Urologia. 2015;82:84–92.

    Article  Google Scholar 

  14. 14.

    D’Elia C, Cerruto MA, Cavicchioli FM, Cardarelli S, Molinari A, Artibani W. Critical points in understanding the Italian version of the IIEF 5 questionnaire. Arch Ital Urol Androl. 2012;84:197–201.

    Google Scholar 

  15. 15.

    Araujo AB, Allen KR, Ni X, Rosen RC. Minimal clinically important differences in the vaginal insertion and successful intercourse items of the sexual encounter profile. J Sex Med. 2012;9:169–79.

    Article  Google Scholar 

  16. 16.

    Cappelleri JC, Stecher VJ. An assessment of patient-reported outcomes for men with erectile dysfunction: Pfizer’s perspective. Int J Impot Res. 2008;20:343–57.

    CAS  Article  Google Scholar 

  17. 17.

    Machin D, Campbell MJ, Fayers P, Pinol A. Statistical tables for the design of clinical studies. edn. 3. Oxford, UK: Blackwell; 1998.

  18. 18.

    Kim ED, McVary KT. Topical prostaglandin-E1 for the treatment of erectile dysfunction. J Urol. 1995;153:1828–30.

    CAS  Article  Google Scholar 

  19. 19.

    Montorsi F, Guazzoni C, Barbieri L, et al. Clinical and hemodynamic effects of transdermal alprostadil for mild arteriogenic impotence: a double-blind placebo controlled study. Int J Impot Res. 1995;7:10–11.

    Google Scholar 

  20. 20.

    Goldstein I, Payton TR, Schechter PJ. A double-blind, placebo-controlled, efficacy and safety study of topical gel formulation of 1% alprostadil (Topiglan) for the in-office treatment of erectile dysfunction. Urology. 2001;57:301–5.

    CAS  Article  Google Scholar 

  21. 21.

    Campbell HE. Clinical monograph for drug formulary review: erectile dysfunction agents. J Manag Care Pharm. 2005;11:151–71.

    Google Scholar 

  22. 22.

    Hanchanale V, Eardley I. Alprostadil for the treatment of impotence. Expert Opin Pharmacother. 2014;15:421–8.

    CAS  Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Paolo Verze.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Cai, T., Palumbo, F., Liguori, G. et al. The intra-meatal application of alprostadil cream (Vitaros®) improves drug efficacy and patient’s satisfaction: results from a randomized, two-administration route, cross-over clinical trial. Int J Impot Res 31, 119–125 (2019).

Download citation

Further reading


Quick links